Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2021 Earnings Conference Call February 28, 2022 8:00 AM ET Company Participants Chas Schultz - Executive Director, Corporate Communications and Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Joseph Stringer - Needham Julian Harrison - BTIG Disclaimer*: This transcript is designed to be used alongside the fre ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Delaware 76-0474169 (I.R.S. Employer Identification Number) 2445 Technology Forest Blvd. ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2021 Earnings Conference Call November 3, 2021 5:00 PM ET Company Participants Chas Schultz - Executive Director of Corporate Communications & Patient Advocacy Lonnel Coats - President and Chief Executive Officer and Director Jeff Wade - Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer. Conference Call Participants Yigal Nochomovitz - Citigroup Jessica Fy ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (281) 863 ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2021 Earnings Conference Call May 6, 2021 6:00 AM ET Company Participants Chas Schultz - Executive Director of Corporate Communications & Patient Advocacy Lonnel Coats - President and Chief Executive Officer and Director Jeff Wade - Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Joseph Stringer - Needham & Company Operator Good morning, good afternoon and good evenin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 Code) or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delawar ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2020 Results Conference Call March 10, 2021 5:00 PM ET Company Participants Chas Schultz - Executive Director of Corporate Communications & Patient Advocacy Lonnel Coats - President and Chief Executive Officer and Director Praveen Tyle - Executive Vice President of Research and Development Jeff Wade - Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer Conference Call Participants Carly Kenselaar - Citigroup Stephen Will ...

(Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the Quarterly Period Ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (Sta ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2020 Earnings Conference Call October 29, 2020 8:00 AM ET Company Participants Chas Schultz – Investor Relations Lonnel Coats – President and Chief Executive Officer Praveen Tyle – Executive Vice President-Research and Development Jeff Wade – Executive Vice President-Corporate and Administrative Affairs and Chief Financial Officer Conference Call Participants Yigal Nochomovitz – Citigroup Kevin Kedra – G.Research Stephen Willey – Stifel Operator Good morning. M ...